UAB Professor in the Department of Cell, Developmental and Integrative Biology and Senior Scientist in the Comprehensive Diabetes Center Sasanka Ramanadham, Ph.D., recently published an review entitled “Fatty acid-mediated signaling as a target for developing type 1 diabetes therapies,” in response to an invitation from the Expert Opinion on Therapeutic Targets journal (PMID: 37706269).

The mission of the journal is to cover novel molecular disease targets while providing expert opinion on their scope for future drug development and the impact on drug discovery.

Ramanadham and co-authors provide an overview of the role of fatty acid in causing β-cell death leading to Type 1 diabetes (T1D). In this context, they expand on the participation of fatty acids in inducing inflammatory responses that promote insulitis and b-cell demise.

“This was a wonderful collaboration among diabetes professionals from around the US,” said Ramanadham. “Our extensive research and commentary shines light on the potential of targeting lipid signaling as avenues to counter T1D development.”